Head to Head Review: H-CYTE (OTCMKTS:HCYTD) & Orthofix Medical (NASDAQ:OFIX)

Orthofix Medical (NASDAQ:OFIX) and H-CYTE (OTCMKTS:HCYTD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Profitability

This table compares Orthofix Medical and H-CYTE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orthofix Medical	-15.18%	-21.25%	-13.29%
H-CYTE	-450.40%	N/A	-777.68%

Valuation & Earnings

This table compares Orthofix Medical and H-CYTE”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orthofix Medical	$799.49 million	0.71	-$151.40 million	($3.29)	-4.43
H-CYTE	$1.61 million	0.32	-$4.80 million	N/A	N/A

H-CYTE has lower revenue, but higher earnings than Orthofix Medical.

Risk & Volatility

Orthofix Medical has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, H-CYTE has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Orthofix Medical and H-CYTE, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orthofix Medical	0	1	4	0	2.80
H-CYTE	0	0	0	0	0.00

Orthofix Medical currently has a consensus target price of $23.33, suggesting a potential upside of 60.04%. Given Orthofix Medical’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Orthofix Medical is more favorable than H-CYTE.

Insider and Institutional Ownership

89.8% of Orthofix Medical shares are held by institutional investors. 2.6% of Orthofix Medical shares are held by insiders. Comparatively, 5.2% of H-CYTE shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Orthofix Medical beats H-CYTE on 8 of the 12 factors compared between the two stocks.

About Orthofix Medical

Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.

About H-CYTE

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.